Krystexxa

Pegloticase (trade name Krystexxa) is a medication for the treatment of severe, treatment-refractory, chronic gout. It is a third line treatment in those in whom other treatments are not tolerated.[1] The drug is administered by infusion intravenously. It was developed by Savient Pharmaceuticals.[2][3] It was approved in the United States in 2010, after two clinical trials found it lowered uric acid levels and reduced deposits of uric acid cryst... [wikipedia]